Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07863609 is registered in ClinicalTrials.gov with Tectonic Operating Company, Inc. as lead sponsor.

NCT NCT07863609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07863609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
Tectonic Operating Company, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht)